Citation Impact
Citing Papers
The Human Tim/Tipin Complex Coordinates an Intra-S Checkpoint Response to UV That Slows Replication Fork Displacement
2007 StandoutNobel
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
1994
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
2000
A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
2003
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel
2003
An Integrated Approach for Analysis of the DNA Damage Response in Mammalian Cells
2015 StandoutNobel
A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System
1999
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines
2000
Clinical studies of reversal of drug resistance based on glutathione
1998
Development of a Panel of 15 Human Ovarian Cancer Xenografts for Drug Screening and Determination of the Role of the Glutathione Detoxification System
2000
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters
2005
Strand-specific Mismatch Repair in Mammalian Cells
1997 StandoutNobel
Cisplatin resistance in human cancers
1991
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Dynamic Covalent Chemistry
2002 StandoutNobel
In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines
1992
Heterogeneous Catalysis through Microcontact Printing
2008 StandoutNobel
cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines
1996
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
1994
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
2000
Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels
1991
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
1997
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance
2010
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts
1993
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
2004
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Gestational trophoblastic disease
2010 Standout
Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin
1994
Paclitaxel (Taxol)
1995 Standout
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
1998
Modifying the properties of platinum(IV) complexes in order to increase biological effectiveness
1999
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines
1994
Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties
2004
The growing applications of click chemistry
2007 Standout
Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance
2006
DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
2002
New Cisplatin Analogues in Development
1993
Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin
1993
The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours
2006
Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines
2003
Molecular mechanisms of cisplatin resistance
2011 Standout
Facile Preparation of Mono‐, Di‐ and Mixed‐Carboxylato Platinum(IV) Complexes for Versatile Anticancer Prodrug Design
2012
Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels
1996
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
2002
Cellular and molecular determinants of cisplatin resistance
1998
Cisplatin and DNA repair in cancer chemotherapy
1995
Preclinical Perspectives on Platinum Resistance
2000
Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines
1991
The growing impact of click chemistry on drug discovery
2003 StandoutNobel
Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
1995
Cisplatin resistance: Preclinical findings and clinical implications
2010
Improvements in the synthesis and understanding of the iodo-bridged intermediate en route to the Pt(IV) prodrug satraplatin
2014
Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin
2002
Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance
2014
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
2000
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
1996
DNA Repair capacity and cisplatin sensitivity of human testis tumour cells
1997
Mechanisms of acquired resistance to cisplatin
1994
Biotransformation of the platinum drug JM216 following oral administration to cancer patients
1996
HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo
1999
Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET
2000
Cellular accumulation of the anticancer agent cisplatin: A review
1993
Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line
1996 StandoutNobel
Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance
2014
Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells
1994
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin
1993
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Inhibitors of HIV‐1 Protease by Using In Situ Click Chemistry
2006 StandoutNobel
New platinum antitumor complexes
1993
Probing the Functional Equivalence of Otoferlin and Synaptotagmin 1 in Exocytosis
2011 StandoutNobel
Intracellular glutathione and cytotoxicity of platinum complexes
1995
Recent insights into platinum drug resistance in cancer
1998
New Developments and Approaches in the Platinum Arena
2000
Excision Repair in Mammalian Cells
1995 StandoutNobel
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
2004
In Situ Click Chemistry: Enzyme‐Generated Inhibitors of Carbonic Anhydrase II
2004 StandoutNobel
Selective Loss of Inner Hair Cells and Type‐I Ganglion Neurons in Carboplatin‐Treated Chinchillas: Mechanisms of Damage and Protection
1999
Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines
1993
DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines
1995
Mechanisms of resistance to cisplatin
2001
Current status of the development of trans-platinum antitumor drugs
2000
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands
2014
Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake
2000
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
1995
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Antitumor activity of imidazole derivatives: dacarbazine and the new alkylating agent imidazene (Review)
2010
Synthesis, Characterization, and Cytotoxicity of a Novel Highly Charged Trinuclear Platinum Compound. Enhancement of Cellular Uptake with Charge
2005
Azole-Based Energetic Salts
2011 Standout
Multidimensional SuFEx Click Chemistry: Sequential Sulfur(VI) Fluoride Exchange Connections of Diverse Modules Launched From An SOF4 Hub
2017 StandoutNobel
In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications
2004 StandoutNobel
Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions †
2000
Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines
2000
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
1993
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Current status of trans-platinum compounds in cancer therapy
2001
Platinum(IV) antitumour compounds: their bioinorganic chemistry
2002
Additions to Metal-Activated Organonitriles
2002 Standout
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Dynamic Combinatorial Chemistry
2006 Standout
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Conformational flexibility and its potential influence on metabolic reactions for the anti-tumour compound a-ammine-bd-bis(butyrato)-cf-dichloro-e-cyclohexylamine platinum(IV)
1996
The Role of DNA Polymerase η in Translesion Synthesis Past Platinum–DNA Adducts in Human Fibroblasts
2004
Platinum Complexes Can Inhibit Matrix Metalloproteinase Activity: Platinum−Diethyl[(methylsulfinyl)methyl]phosphonate Complexes as Inhibitors of Matrix Metalloproteinases 2, 3, 9, and 12
2007
Mechanistic Insight into the Inhibition of Matrix Metalloproteinases by Platinum Substrates
2009
Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct.
1996 StandoutNobel
Human Testis-Determining Factor SRY Binds to the Major DNA Adduct of Cisplatin and a Putative Target Sequence with Comparable Affinities
1998
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance
1999
Modification of Platinum(II) Antitumor Complexes with Sulfur Ligands. 1. Synthesis, Structure, and Spectroscopic Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO3and [{PtCl(diamine)}2(L-L)](NO3)2(L = Monofunctional Thiourea Derivative; L-L = Bifunctional Thiourea Derivative)
1998
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Platinum resistance: Laboratory findings and clinical implications
1993
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
1994
Polymeric derivatives of activated cyclophosphamide as drug delivery systems in antitumor chemotherapy. Pharmacologically active polymers, 20
1979
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
1992
In Situ Selection of Lead Compounds by Click Chemistry: Target-Guided Optimization of Acetylcholinesterase Inhibitors
2005 StandoutNobel
Click chemistry in materials synthesis. 1. Adhesive polymers from copper‐catalyzed azide‐alkyne cycloaddition
2004 StandoutNobel
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
2002
New Therapies for Ovarian Cancer
1992
Efficient Templated Synthesis of Donor−Acceptor Rotaxanes Using Click Chemistry
2006 StandoutNobel
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Self-Assembling Cytotoxins
1986 Science
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
1994
Structure and properties of pharmacologically active polymers
1975
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Cu-Catalyzed Azide−Alkyne Cycloaddition
2008 StandoutNobel
Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
1992
Repair of DNA–polypeptide crosslinks by human excision nuclease
2006 StandoutNobel
Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B
1994
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
1994
Synthesis and in Vitro Antitumor Activity of Platinum Acetonimine Complexes
2006
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
1999
The current status of new platinum analogs.
1992
Peptide Targeting of Platinum Anti-Cancer Drugs
2009
Works of G Abel being referenced
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines
1992
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes
1992
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
1991
Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery
1992
Synthesis and cytotoxicity of potential tumor-inhibitory analogs of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl
1993
Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro
1994
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes
1989
Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
1992
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
1992
The selective concentration of sulphadiazine and related compounds in malignant tissue
1973
Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
1992
In vitro metabolic activation of 1-p-carboxamidophenyl-3,-3-dimethyltriazene to cytotoxic products
1977
Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
1992
Cytotoxic sulphonamides designed for selective deposition in malignant tissue
1975